In France, as in other European countries, management of prostate cancer in the population is rather variable. The objective was to analyse diagnosis and treatment modalities of prostate cancer in patients from French cancer registries.
Introduction
Prostate cancer is the most frequent cancer in men over 50 y, with an increasing incidence related to age. 1, 2 In most European countries, the incidence of prostate cancer has risen more than that of any other cancer over the past two decades, explained in part by the large use of PSA and ultrasonography. 3, 4 In France, 26 474 new cases of prostate cancer were diagnosed in 1995 with a mortality of 9263 deaths. 5 Over the last 10 y, PSA testing and new diagnostic procedures have changed the clinical presentation of prostate cancer, with a greater detection at a localized stage, which is more accessible to curative treatment. 6 As in most European countries, management of prostate cancer is variable in the French population and may be undertaken either in public hospitals or in private clinics. In this context, only population based studies from population registers can provide valid information on management.
Optimum management of this cancer remains controversial and the results of large randomized trials in Europe and the USA will not be available for another decade. 7 The Comité de Cancérologie de l'Association Franc¸aise d'Urologie (CCAFU) and the French network of cancer registries (Francim) decided to perform a descriptive study of a representative sample of cases diagnosed in 1995 in four French regions with a cancer registry, regarding clinical presentation, diagnosis and treatment. This survey provides the first baseline to clinicians and public health authorities on the situation of prostate cancer in France with a recent descriptive analysis of clinical practice.
Patients and methods
Our study population consisted of 803 men with prostate cancer diagnosed during 1995 from four of the eight French cancer registries covering the following geographical regions: Bas-Rhin; Calvados; Isère; and Tarn. A sample of 200 randomly selected cases in the database of each registry was estimated representative regarding the number of prostate cancer diagnosed annually in these regions ( Figure 1 ). Prostate cancer incidence in 1995 in the four regions is presented in Table 1 .
These four regions were chosen because they are situated in distant parts of France (NE, NW and SW) and represent 3 million inhabitants (about 6% of the French population) with disparities in urbanization (Tarn and Calvados were more rural) and health care distribution (no university hospital in Tarn, Comprehensive Cancer Centres only in Calvados and Bas-Rhin). There was some discrepancy in urologist distribution, especially in the SW of France where the urologists of the private sector were more numerous than in the NE and NW. Radiotherapist distribution was nearly equivalent regarding the number of inhabitants in each region, excepted in Calvados where the density of radiotherapists was higher in private and public sectors.
Definitive analysis concerned only 798 patients as five patients were excluded because of concomitant bladder carcinoma which required radical cystoprostatectomy as prior treatment. Social and demographic characteristics of the patients, tumour characteristics, and diagnostic and treatment procedures were collected retrospectively from the medical records by investigators from each registry in 1998. This information was recorded on a questionnaire prepared previously by CCAFU members. Various medical indicators were defined: clinical (urinary symptoms, findings of digital rectal examination); diagnostic (biopsies, transurethral resection); and the different treatments. The clinical staging of the tumour was coded after centralized reviewing of all the questionnaires in 1999, on the basis of the 1992 Tumour-Node-Metastasis (TNM) classification, because of the period of the study. We categorized the main treatments performed in the year following diagnosis into five groups: radical prostatectomy; radiotherapy; hormonal therapy; endoscopic resection; and expectant management. The distributions were analyzed using the chi-square test. Multivariate analysis by logistic regression was used to describe the medical determinants of the various treatment choices, taking into account simultaneously age, PSA and clinical staging of the tumour. In this model, the results were expressed as an adjusted odds ratio (aOR) which reflected the probability of having the treatment studied for a given category of patients compared with another group of patients considered as the reference category. Clinical stage T 1 , age between 60 -69 y and PSA values between 4 -10 ng/ml were chosen as these reference categories. The Wald test was performed in order to test each variable modality. All analyses were done using Stata software. 8 
Results
The population of 798 patients was divided into 10-y age groups ( Figure 2 ). Mean age at diagnosis was 71.6 y (46 -94 y) with 365 patients (43.3%) aged less than 70 y and 160 patients (20%) over 80 y ( Table 2) .
Circumstances of diagnosis
At diagnosis, 73.2% of patients described urinary symptoms and 4.6% described signs related to metastasis, usually bony ( Table 2 ). The symptoms increased significantly with age (P<0.0001).
PSA value PSA had been tested in 737 cases (92.4%), in particular in patients aged less than 80 y (P<0.0001). Only 268 patients Figure 1 Geographical repartition of the 798 patients in the four French departments studied. Prostate cancer in France M Soulié et al (33.6%) had had earlier surveillance by PSA determination before the diagnosis (Table 2 ). Median PSA rate was 18.2 ng/ml (normal<4 ng/ml). A value of PSA <10 ng/ml was observed in 23.8% and PSA over 50 ng/ ml in 20.6%.
Digital rectal examination (DRE)
In 64 cases (8%), no data concerning DRE was provided at diagnosis. Across all age groups, DRE was considered suspicious of cancer in 499 patients. In these patients, the tumour was estimated to be organ-confined in 80%, extraprostatic in 9% and unspecified in 11%.
Diagnostic modalities and evaluation of the extent of prostate cancer
Diagnosis was done by transrectal needle biopsy in 63.4% of patients and 75% of them had a PSA > 4 ng/ml ( Figure  3 ). When the technique of biopsy was stated (in 228 patients), a minimum of six echoguided transrectal needle biopsies were performed. Diagnosis was performed by transurethal resection of the prostate (TURP) in 31.9% of patients and 68% of them had a PSA <4 ng/ml. The frequency of prostate biopsies decreased with age, especially after the age of 70, whereas inversely the frequency of TURP increased (P<0.002).
The extent of disease was assessed with bone scan and pelvic CT scan (Table 3) . They were markedly less used in the oldest patients. About 75% of bone scans concerned patients with PSA > 10 ng/ml. The exam was considered as abnormal in 107 cases (23.2%).
When PSA was <30 ng/ml, CT scan was considered normal in 88% of the 233 patients. Of the 108 patients with PSA > 30 ng/ml, CT scan showed macroscopic ilio-obturator nodes and extraprostatic involvement in 28% of them.
Clinical staging
Clinical staging was assessed on DRE and on the extent of disease. The tumour was localized to the prostate (T 1 , T 2 ) in 60%. Metastatic involvement of lymph nodes or bone was observed in 17% ( Figure 2 ). There was an association between the PSA done previously and clinical staging. The patients who had had at least one PSA determination before diagnosis were diagnosed at an earlier clinical stage: 155 T 1 (58%) and 65 T 2 (24%); (P<0.0001).
Treatment modalities
The treatments used are presented in Figure 4 . They were performed either alone or in combination. In Table 4 , the frequency of the different treatments was defined according to the medical determinants: age of patients; PSA rate; and clinical staging of the tumour.
Radical prostatectomy (RP)
Of the 180 RPs performed in this population, 175 were done in the year following diagnosis (22% of main 
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M Soulié et al treatment) and half were performed within 50 days of diagnosis. RP was used alone in 122 cases and was complemented by adjuvant treatment in 53 cases. Logistic regression showed that radical prostatectomy was most often performed in patients aged less than 60 y, that it was about three times more frequent in patients with PSA rates between 4 and 20 ng/ml than in the other patients and three times more frequent for clinical stage T 2 than for stages T 1 , T 3 and T 4 ( Table 4) .
External beam radiotherapy
Pelvic radiotherapy was a little less frequent than RP (19.4% of treatment) and patients were older than those who had RP.
Logistic regression showed that external beam radiotherapy was about twice as frequent for stages T 3 -4 than for stages T 2 , N þ and metastatic tumours and three times more frequent than for stage T 1 tumours. Its frequency increased slightly with age until the age of 80 but then decreased markedly. It was about twice as frequent for PSA levels between 20 and 50 ng/ml than for levels below 10 ng/ml.
Hormonal therapy
Hormonal therapy was used in 264 patients (33%) and was the most frequent treatment in this population. It consisted of either surgical castration (55 cases) or hormonal castration (209 cases). Logistic regression showed a markedly increased probability of having hormonal therapy in the oldest patients and advanced tumours (Table 4) . Thus, 38.6% of patients treated by hormonal therapy had metastatic cancer and 43% had a PSA level greater than 50 ng/ml.
TURP and expectant management
TURP and expectant management were grouped together in the multivariate analysis as opposed to conventional treatment. TURP is a surgical procedure to relieve urethral obstruction but is not able to treat the cancer itself. In this group, 141 patients (17.7%) who underwent TURP as the only treatment were included as well as 49 patients (6%) with expectant management in the year following diagnosis. More than 50% of patients with a T 1 tumour or with a PSA rate <4 ng/ml had TURP alone.
Logistic regression confirmed these preferential indications for early tumours and also showed that for equivalent tumour development, TURP was significantly more frequent in the oldest patients (about twice as frequent).
In all, 749 patients (94%) received treatment in the year following diagnosis. This treatment was specific for prostate cancer in about 75% and had a curative intention (RP or external radiotherapy) in over 40% of cases.
Discussion
The public and the health services in most European countries are increasingly interested in prostate cancer for medical reasons and economic costs. The practice of health care in oncology has rarely been evaluated in the general French population except for colorectal cancer. 9 In 1989, recommendations on management and screening of prostate cancer in France were published, but no information on their application and on assessment of practices in the general population was provided. 10 This population based study carried out by the CCAFU and FRANCIM network aimed to analyse clinical data from four French cancer registries with sufficient social, Prostate cancer in France M Soulié et al demographic and geographical disparities for the epidemiology to be representative of prostate cancer in France. The mean age (71.6 y) of this population was normal for this disease of 'aging' men. 11 Three-quarters of patients had urological symptomatology and 90% had PSA determination. In a third of cases, PSA was done prior to the diagnosis, but it is not possible to conclude whether these repeated PSA measurements corresponded to a screening process or an attitude of surveillance in the context of a benign prostate disorder. Cancer was suspected on DRE in more than two-thirds of cases, suggesting a large proportion of tumours had reached stage T 2 at least. Prostate cancer was diagnosed by prostate biopsy (63%), or TURP (32%) either in initial benign hypertrophy of the prostate with normal PSA levels or in locally advanced tumour. The proportion of patients diagnosed by TURP (T 1a and T 1b stage) remained high in this series. During the same period, the proportion of patients whose cancer was detected by TURP alone in the southern part of The Netherlands decreased considerably from 30% in 1988 -1990 to 10% in 1994 -1996 . 12 The proportion of stage T 1c in our series was about 20%. This result is markedly lower than those reported by Stamey, in which stage T 1c increased from 10% in 1988 to over 70% in 1996. But, this population of US patients is different because of selected cases in a referent medical centre and a screening approach. 13 Current diagnosis trends show that T 1c becomes the most common circumstance of diagnosis of prostate cancer in Europe. 11 However, prostate cancer registration in four of the six Swedish regions showed large geographical variations in incidence and localized tumours especially concerning T 1c tumours. High incidence was associated with a larger proportion of localized tumours, early age at diagnosis and more often curative treatment. 14 More than 60% of patients had clinically organ-confined tumours (T 1 and T 2 ) in our series. This result is lower than that observed in the southern part of The Netherlands, where 75% of prostate cancer cases diagnosed between 1988 and 1996 had localized disease. During the same period, the proportion of advanced prostate cancers decreased from 33% to 19%. 12 These findings are in accord with North American data which showed markedly earlier stage at diagnosis during the study period. 3, 7 In contrast, 60% of patients with prostate cancer in the United Kingdom are diagnosed with metastatic disease. 15 In our series, 40% of patients had a curative treatment of surgery or radiotherapy. The frequency of RP (22%) may seem low according to the 60% of T 1 or T 2 tumours, but only 43% of patients were aged less than 70. In contrast, radiotherapy was the most frequently applied treatment for patients aged between 65 and 75 y especially in T 3 tumours and PSA levels between 20 and 50 ng/ml. No conclusive evidence of superiority of one of these two curative options is currently available in localized cancer, although most patient series suggest a better outcome for surgically treated patients than for irradiated patients. 16 -18 Hormonal treatment was the main treatment of advanced disease in older patients, especially those aged over 80 y. Expectant management and TURP accounted for 23% of treatment, in particular for infraclinical disease (T 1 ) or weakly aggressive forms with PSA levels below 4 ng/ml in patients aged over 70 y. As reported in the literature, expectant management of prostate cancer may be debatable in younger patients. 7, 19 Data are lacking in this study to differentiate stages T 1a and T 1b in the group of patients under surveillance or treated by TURP alone. A multivariate analysis on the influence of non-medical determinants such as geographical region and sector of activity (public and private) on the different treatment choices will be provided in a subsequent publication.
We have to stress the cost and the difficulty of collecting retrospective data from patient records within the various organizations intervening in the management of prostate cancer in France. In particular, it is very difficult to decide whether the patient was in fact undergoing screening according to the inaccurate circumstances of diagnosis. These difficulties can explain the rarity of such studies in other European countries and the exceptional publications from European medical institutions on this subject. 11, 12, 14 
Conclusion
This study on prostate cancer management in a sample of the general population of a country is one of the first performed in Europe and particularly in France. It provides a data source to French clinicians and public health authorities on the situation of the disease in 1995. Prostate cancer was clinically localized in 60% of cases whereas the mean age of the population remained high. About 75% of the patients were treated specifically for their prostate cancer in the year following diagnosis, with a curative intention in 40%.
A 5 y-follow-up study of this population is currently underway to assess patient survival and the efficacy of the various treatments. This survey will be useful to compare future descriptive analysis and to report on changing clinical practice.
